Esthesioneuroblastoma (olfactory neuroblastoma): lines of therapy
5 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Screening, prevention and diagnosis | 1 |
| Early / localised | 1 |
| Advanced, first line | 2 |
| Other settings | 1 |
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diagnosis and staging | Endoscopic biopsy with immunohistochemistry, MRI and CT of the sinuses and skull base, neck imaging, DOTATATE PET where available. | NCCN Guidelines: Head and Neck Cancers (ethmoid and maxillary sinus tumours) | 95 |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Resectable disease | Endoscopic endonasal or craniofacial resection with skull base reconstruction by a skull base team, followed by postoperative radiotherapy (intensity-modulated or proton) for nearly all patients. | NCCN Guidelines: Head and Neck Cancers (ethmoid and maxillary sinus tumours) | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | High-grade or advanced disease (Hyams III to IV, Kadish C to D) | Induction cisplatin and etoposide, then surgery and radiotherapy or definitive chemoradiotherapy; elective neck irradiation considered. | NCCN Guidelines: Head and Neck Cancers (ethmoid and maxillary sinus tumours) | 93 | |
| All comers | Recurrent or metastatic disease | Repeat surgery or re-irradiation for local relapse; lutetium-177 dotatate for somatostatin-receptor-positive disease; platinum-etoposide or temozolomide; trials. | NCCN Guidelines: Head and Neck Cancers (ethmoid and maxillary sinus tumours) | 89 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Follow-up | MRI surveillance indefinitely because of late relapse; management of anosmia, cerebrospinal fluid leak and visual effects. | NCCN Guidelines: Head and Neck Cancers (ethmoid and maxillary sinus tumours) | 40 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.